A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas

Trial Profile

A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Fluorouracil (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 05 Dec 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 02 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top